Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, Lonardi S, Zagonel V, Lenz HJ, Loupakis F. Battaglin F, et al. Among authors: lonardi s. Expert Rev Anticancer Ther. 2018 Mar;18(3):251-266. doi: 10.1080/14737140.2018.1428092. Epub 2018 Jan 19. Expert Rev Anticancer Ther. 2018. PMID: 29338550 Free PMC article. Review.
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, Piro G, Cavaliere A, Deiana M, Valenti MT, Bazan D, Fedele V, Lonardi S, Melisi D. Merz V, et al. Among authors: lonardi s. Clin Cancer Res. 2020 Sep 1;26(17):4661-4669. doi: 10.1158/1078-0432.CCR-20-0395. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532788 Clinical Trial.
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Lonardi S, Nimeiri H, Xu C, Zollinger DR, Madison RW, Fine AD, Gjoerup O, Rasola C, Angerilli V, Sharma S, Wu HT, Palsuledesai CC, Malhotra M, Aleshin A, Loupakis F, Renkonen E, Hegde P, Fassan M. Lonardi S, et al. Int J Mol Sci. 2022 Sep 29;23(19):11529. doi: 10.3390/ijms231911529. Int J Mol Sci. 2022. PMID: 36232827 Free PMC article.
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
Overman MJ, Gelsomino F, Aglietta M, Wong M, Limon Miron ML, Leonard G, García-Alfonso P, Hill AG, Cubillo Gracian A, Van Cutsem E, El-Rayes B, McCraith SM, He B, Lei M, Lonardi S. Overman MJ, et al. Among authors: lonardi s. J Immunother Cancer. 2024 May 31;12(5):e008689. doi: 10.1136/jitc-2023-008689. J Immunother Cancer. 2024. PMID: 38821718 Free PMC article. Clinical Trial.
Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
Battaglin F, Dadduzio V, Bergamo F, Manai C, Schirripa M, Lonardi S, Zagonel V, Loupakis F. Battaglin F, et al. Among authors: lonardi s. Expert Opin Biol Ther. 2017 Oct;17(10):1297-1308. doi: 10.1080/14712598.2017.1356815. Epub 2017 Jul 28. Expert Opin Biol Ther. 2017. PMID: 28752777 Review.
Immunotherapy in Gastrointestinal Cancers.
Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S. Procaccio L, et al. Among authors: lonardi s. Biomed Res Int. 2017;2017:4346576. doi: 10.1155/2017/4346576. Epub 2017 Jul 3. Biomed Res Int. 2017. PMID: 28758114 Free PMC article. Review.
594 results